Imfinzi (durvalumab) - AstraZeneca
APVO436 - Medexus
Opdivo (nivolumab) - BMS
magrolimab (ONO-7913) - Ono Pharma
Keytruda (pembrolizumab) - Merck (MSD)
flotetuzumab (MGD006) - MacroGenics
https://library.ehaweb.org/eha/2024/eha2024-congress/419883/moazzam.shahzad.outcomes.with.immune-based.therapies.for.tp53.mutated.acute.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D2%2Ace_id%3D2552%2Aot_id%3D29192%2Amarker%3D5100%2Afeatured%3D18527
 
Moazzam Shahzad; Ahmad Basharat; Muhammad Fareed Khalid; Jawad Noor; Muhammad Kashif Amin; iqra anwar; Mohamed Kharfan-Dabaja; Talha Badar
 
May 15, 2024
 
Next